ITB-MED was founded in 2016 with over 35 employees in offices in Stockholm and New York. Clinical Trials are being executed globally with a particular focus on the United States (US) and the European Union (EU) with an aim to submit applications for market authorization of siplizumab. We are expanding rapidly and moving into a combined lab and office space in “Forskaren”, Stockholm’s new life science center, in 2024.